


**Product Name** : GSK2636771  
**Cat. No.** : PC-21944  
**CAS No.** : 1372540-25-4  
**Molecular Formula** : C<sub>22</sub>H<sub>22</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>  
**Molecular Weight** : 433.43  
**Target** : PI3K  
**Solubility** : 10 mM in DMSO



## Biological Activity

GSK2636771 is a potent, selective and orally bioavailable inhibitor of PI3K $\beta$  with  $K_i$ /IC<sub>50</sub> of 0.89/5.2 nM, respectively. GSK2636771 displays 900-fold selectivity over p110 $\alpha$  and p110 $\gamma$ , and 10-fold selectivity over p110 $\delta$  isoforms. GSK2636771 causes cell viability significantly more decreased in the control cells (p110 $\beta$ -reliant PTEN-deficient PC3 prostate and BT549 and HCC70 breast cancer cell lines) than in PTEN-mutant and PTEN wild-type EEC cells. GSK2636771 decreases AKT phosphorylation in prostate and breast cancer cell lines, suppresses cell and tumor growth in vivo.

## References

Weigelt B, et al. Clin Cancer Res. 2013 Jul 1;19(13):3533-44.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com